Giangaspero F, Fratamico F C, Ceccarelli C, Brisigotti M
Istituto di Anatomia ed Istologia Patologica, Università di Bologna, Italia.
Appl Pathol. 1989;7(2):134-44.
An immunocytochemical study using a panel of commercially available antisera, has been performed to distinguish on the basis of their immunoreactivity a series of spindle cell sarcomas diagnosed solely on the histologic features: 11 malignant schwannomas (MS), 8 leiomyosarcomas (LMS) and 3 malignant fibrous histiocytomas (MFH). The results have been compared with those obtained in 12 benign and 8 malignant peripheral nerve sheath tumors (MPNST) in which the microscopic diagnosis was supported by their origin in a nerve trunk and/or in von Recklinghausen's (vR) disease. The following antisera were used: anti-S-100 protein, anti-Leu-7, anti-neuron specific enolase (NSE), anti-myelin basic protein (MBP), anti-glial fibrillary acidic protein (GFAP) and anti-actin. S-100 protein was present in 100% of benign and malignant peripheral nerve tumors and in 7/11 (63%) of MS diagnosed on histological basis only and in 3/8 (37%) LMS. MFH were negative. Leu-7 positivity was observed in 8/12 (66%) and 6/8 (75%), respectively, in benign and malignant PNS neoplasms, in 5/11 (45%) MS, 4/8 (50%) LMS and 2/3 (66%) MFH. NSE was present in 7/12 (58%) and 6/8 (75%), respectively, in benign and malignant PNS tumors, in 6/11 (54%) MS and in 1/8 (12%) LMS. MFH were negative. MBP resulted negative in peripheral nerve neoplasms and spindle cell sarcomas. GFAP positivity was observed in 2/12 (16%) and 1/8 (12%), respectively, in benign and malignant PNS neoplasms. All spindle cell sarcomas were negative. All cases of MPNST and spindle cell sarcomas showed actin immunoreactivity. These results indicate that: (1) MBP, Leu-7 and NSE do not represent markers of schwannian differentiation; (2) GFAP, although rarely expressed, may indicate schwannian differentiation, and (3) malignant peripheral nerve neoplasms and LMS share immunoreactivity for S-100, Leu-7, NSE and actin, therefore they cannot be differentiated on immunocytochemical basis using commercially available antisera.
一项免疫细胞化学研究利用一组市售抗血清，根据其免疫反应性对一系列仅根据组织学特征诊断的梭形细胞肉瘤进行区分：11例恶性神经鞘瘤（MS）、8例平滑肌肉瘤（LMS）和3例恶性纤维组织细胞瘤（MFH）。研究结果与12例良性和8例恶性周围神经鞘瘤（MPNST）的结果进行了比较，这些肿瘤的显微镜诊断依据是它们起源于神经干和/或冯雷克林霍增氏病（vR）。使用了以下抗血清：抗S-100蛋白、抗Leu-7、抗神经元特异性烯醇化酶（NSE）、抗髓磷脂碱性蛋白（MBP）、抗胶质纤维酸性蛋白（GFAP）和抗肌动蛋白。S-100蛋白在所有良性和恶性周围神经肿瘤中均存在，在仅根据组织学诊断的MS中占7/11（63%），在LMS中占3/8（37%）。MFH均为阴性。Leu-7阳性在良性和恶性PNS肿瘤中分别为8/12（66%）和6/8（75%），在MS中为5/11（45%），在LMS中为4/8（50%），在MFH中为2/3（66%）。NSE在良性和恶性PNS肿瘤中分别为7/12（58%）和6/8（75%），在MS中为6/11（54%），在LMS中为1/8（12%）。MFH均为阴性。MBP在周围神经肿瘤和梭形细胞肉瘤中均为阴性。GFAP阳性在良性和恶性PNS肿瘤中分别为2/12（16%）和1/8（12%）。所有梭形细胞肉瘤均为阴性。所有MPNST和梭形细胞肉瘤病例均显示肌动蛋白免疫反应性。这些结果表明：（1）MBP、Leu-7和NSE不代表雪旺氏分化的标志物；（2）GFAP虽然很少表达，但可能表明雪旺氏分化；（3）恶性周围神经肿瘤和LMS在S-100、Leu-7、NSE和肌动蛋白方面具有共同的免疫反应性，因此使用市售抗血清无法在免疫细胞化学基础上对它们进行区分。
